Publikationsdatenbank

Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children (2021)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Mugo, Robert M. (WE 6)

Mwai, Kennedy

Mwacharo, Jedidah

Shee, Faiz M.

Musyoki, Jennifer N.

Wambua, Juliana

Otieno, Edward

Bejon, Philip

Ndungu, Francis M. (WE 6)

Quelle

Malaria Journal

Bandzählung: 20

Heftzählung: 1

Seiten: Article number: 452

ISSN: 1475-2875

Sprache

Englisch

Verweise

URL (Volltext): https://malariajournal.biomedcentral.com/articles/10.1186/s12936-021-03961-2

DOI: 10.1186/s12936-021-03961-2

Pubmed: 34856981

Kontakt

Institut für Immunologie

Robert-von-Ostertag-Str. 7-13
14163 Berlin
+49 30 838 51834
immunologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Background:
RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/AS01-induced antibodies was investigated.

Methods:
150 participants were randomly selected from the 447 children who participated in the RTS,S/AS01 phase IIb clinical trial in 2007 from Kilifi-Kenya. Cumulatively, the retrospective follow-up period was 93 months with annual plasma samples collection. The levels of anti-CSP IgM, total IgG, IgG1, IgG2, IgG3, and IgG4 antibodies were then determined using an enzyme-linked immunosorbent assay.

Results:
RTS,S/AS01 induced high levels of anti-CSP IgG antibodies which exhibited a rapid waning over 6.5 months post-vaccination, followed by a slower decay over the subsequent years. RTS,S/AS01-induced anti-CSP IgG antibodies remained elevated above the control group levels throughout the 7 years follow-up period. The anti-CSP IgG antibodies were mostly IgG1, IgG3, IgG2, and to a lesser extent IgG4. IgG2 predominated in later timepoints. RTS,S/AS01 also induced high levels of anti-CSP IgM antibodies which increased above the control group levels by month 3. The controls exhibited increasing levels of the anti-CSP IgM antibodies which caught up with the RTS,S/AS01 vaccinees levels by month 21. In contrast, there were no measurable anti-CSP IgG antibodies among the controls.

Conclusion:
RTS,S/AS01-induced anti-CSP IgG antibodies kinetics are consistent with long-lived but waning vaccine efficacy. Natural exposure induces anti-CSP IgM antibodies in children, which increases with age, but does not induce substantial levels of anti-CSP IgG antibodies.